[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332453-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-332453-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","sept9-from-pan-cancer-to-lung-squamous-cell-carcinoma-research-findings","SEPT9: From Pan-Cancer to Lung Squamous Cell Carcinoma - Research Findings","","SEPT9 is a cytoskeletal GTPase controlling key processes such as mitosis and cytokinesis. Prior work suggested links between SEPT9 and tumorigenesis, but comprehensive pan-cancer characterization was lacking. Using public gene and protein expression data, the study evaluates SEPT9 for cancer screening, prognosis, and treatment relevance, then validates findings with clinical samples from 90 lung squamous cell carcinoma patients. Molecular docking supports drug-binding associations, and an integrative spindle-associated prognostic model refines outcome prediction and immune microenvironment modulation.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sept9-from-pan-cancer-to-lung-squamous-cell-carcinoma-research-findings/332453/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sept9-from-pan-cancer-to-lung-squamous-cell-carcinoma-research-findings/332453.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"How does SEPT9 relate to treatment and drug response?","Question",{"text":63,"@type":64},"Functional enrichment, single-cell expression, and immune infiltration analyses indicate SEPT9 promotes malignant progression and reshapes immune microenvironments. Molecular docking and drug-sensitivity analyses suggest SEPT9 is linked to sensitivity and resistance to multiple drugs with stable binding, supporting potential therapeutic relevance.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},332453,1790194810,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":109,"language":131,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":12,"update_tm":135,"read_time":96,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Wang et al. BMC Cancer (2024) 24:1105 [https://doi.org/10.1186/s12885-024-12877-4](https://doi.org/10.1186/s12885-024-12877-4)  \nBMC Cancer  \n RESEARCH Open Access  \nSEPT9: From pan-cancer to lung squamous   cell carcinoma  \nWenwen Wang1†, Xiaochen Zhang2†, Ping Gui3, Qizhen Zou1, Yuzhou Nie4, Shenglin Ma5 and Shirong Zhang1*  \nAbstract  \nBackground SEPT9 is a pivotal cytoskeletal GTPase that regulates diverse biological processes encompassing mitosis and cytokinesis. While previous studies have implicated SEPT9 in tumorigenesis and development; comprehensive pan-cancer analyses have not been performed. This study aims to systematically explore its role in cancer screening, prognosis, and treatment, addressing this critical gap.  \nMethods Gene and protein expression data containing clinical information were obtained from public databases for pan-cancer analyses. Additionally, clinical samples from 90 patients with lung squamous cell carcinoma (LUSC) were used to further experimentally validate the clinical significance of SEPT9 . In addition, the molecular docking tool was used to analyze the affinities between SEPT9 protein and drugs.  \nResults SEPT9 is highly expressed in various cancers, and its aberrant expression correlates with genetic alternationsand epigenetic modifications, leading to adverse clinical outcomes. Take LUSC as an example, additional dataset analyses and immunohistochemical experiments further confirm the diagnostic and prognostic values as well as the clinical relevance of the SEPT9 gene and protein. Functional enrichment, single-cell expression, and immune infiltration analyses revealed that SEPT9 promotes malignant tumor progression and modulates the immune microenvironments, enabling patients to benefit from immunotherapy. Moreover, drug sensitivity and molecular docking analyses showed that SEPT9 is associated with the sensitivity and resistance of multiple drugs and has stable binding activity with them, including Vorinostat and OTS-964 . To harness its prognostic and therapeutic potential in LUSC, a mitotic spindleassociated prognostic model including SEPT9, HSF1, ARAP3, KIF20B, FAM83D, TUBB8, and several clinical characteristics, was developed. This model not only improves clinical outcome predictions but also reshapes the immune microenvironment, making immunotherapy more effective for LUSC patients.  \nConclusion This is the first study to systematically analyze the role of SEPT9 in cancers and innovatively apply the mitotic spindle-associated model to LUSC, fully demonstrating its potential as a valuable biomarker for cancer screening and prognosis, and highlighting its application value in promoting immunotherapy and chemotherapy, particularly for LUSC.  \nKeywords Drug therapy, Immunotherapy, LUSC, Prognostic model, SEPT9, Tumor immune microenvironment  \n†Wenwen Wang and Xiaochen Zhang contributed equally to this work.  \n*Correspondence: Shirong Zhang [shirleyz4444@163.com](shirleyz4444@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyr","cbCaikRTcMVlnBPf","https://ap.wps.com/l/cbCaikRTcMVlnBPf","pdf",25473880,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## Cancer context and need for biomarkers\n## Septins and SEPT family overview\n## Focus on SEPT9","[{\"question\":\"How does SEPT9 relate to treatment and drug response?\",\"answer\":\"Functional enrichment, single-cell expression, and immune infiltration analyses indicate SEPT9 promotes malignant progression and reshapes immune microenvironments. Molecular docking and drug-sensitivity analyses suggest SEPT9 is linked to sensitivity and resistance to multiple drugs with stable binding, supporting potential therapeutic relevance.\"}]","SEPT9: From Pan-Cancer to Lung Squamous Cell Carcinoma - Research Findings | PDF",1789998250]